patient_outcomes

NEW YORK – October 30, 2026 -- The Galien Foundation marked the 20th anniversary of the Prix Galien USA Awards at the American Museum of Natural History, adding a new Patient First Award and presenting international honors alongside the U.S. prizes.

Eight U.S. categories judged by a 51-member panel

Winners were selected by the Prix Galien USA Committees, which comprise 25 committee members, 11 subcommittee members and 15 advisory board members. Three Nobel Laureates sit on the panels. The U.S. awards covered eight categories: Best Biotechnology Product, Best Pharmaceutical Product, Best Product for Rare/Orphan Diseases, Best Medical Technology, Best Digital Health Solution, Incubators, Accelerators and Equity, Prix Galien EcoHealth, and Best Startup.

THE BRONX – October 29, 2026 -- Holliswood Center and Bushwick Center, two skilled nursing facilities in the Centers Health Care network, have earned the American Heart Association's Skilled Nursing Facility Heart Failure Certification, aimed at cutting preventable readmissions in a patient population projected to exceed 8 million U.S. adults by 2030.

Certification audits six operating areas of heart failure care

The framework evaluates facilities against science-based requirements for heart failure (HF) patients. The six areas are program management, staff education, patient and caregiver education and support, care coordination, clinical management and quality improvement.

Moshe Blackstein, administrator at Amsterdam Nursing Home, another Centers Health Care facility, said the certification reflects a multidisciplinary team approach and tighter communication and coordination at every stage of care.

Maastricht – October 14, 2026 -- More than half of respondents to the MAPPA patient survey received a primary immunodeficiency (PID) diagnosis after age 18, and 28% reported permanent damage at the time of diagnosis, according to preliminary findings Kedrion Biopharma and AIP APS will present at ESID 2026.

MAPPA survey expands from Italy to Portugal, Spain and Turkey

The survey was developed by AIP APS, the Italian Association for Primary Immunodeficiencies, in collaboration with Kedrion. It collects real-world data on the experiences of people living with PIDs across Europe. The expansion from Italy to Portugal, Spain and Turkey is expected to provide new evidence on patient pathways, diagnostic journeys and unmet needs.

AIP APS President Alessandro Segato said that turning patient experiences into evidence helps identify shared needs that might otherwise remain unseen, and can strengthen diagnosis, care and support at a European level.

Doylestown, Pa. – October 07, 2026 -- Nordic Pharma, Inc., a subsidiary of SEVER Life Sciences B.V., will present new patient data for its LACRIFILL Canalicular Gel at the American Academy of Ophthalmology (AAO) Annual Meeting in New Orleans, running October 9-12.

More than 2,200 U.S. practices now use LACRIFILL Canalicular Gel

The company reports that over 2,200 ophthalmology and optometry practices across the United States have adopted the gel for patients undergoing cataract or refractive surgery and for managing dry eye disease. More than 130,000 patients have been treated with the therapy to date.

Patient survey shows 96% report improved comfort after cataract surgery

In Nordic Pharma's latest patient experience survey, 96% of respondents who had cataract surgery within the past six months said LACRIFILL Canalicular Gel made their eyes feel better. Among all surveyed patients, 91% reported the same improvement.

Fountain Valley, Calif. – September 21, 2026 -- MemorialCare's Long Beach Medical Center and Saddleback Medical Center have received the American Heart Association's Get With The Guidelines® - Stroke Gold Plus quality achievement award, recognizing stroke treatment aligned with nationally validated clinical guidelines. Long Beach Medical Center additionally earned the Get With The Guidelines® - Heart Failure Gold Plus award for reducing readmissions and increasing healthy days at home for heart failure patients.

Long Beach Medical Center collects four additional Target Honor Roll designations

Long Beach Medical Center received the Target: Stroke Honor Roll Elite Plus, Advanced Therapy, Target: Type 2 Diabetes Honor Roll, and Target: Heart Failure Honor Roll Optimal. Saddleback Medical Center secured the Target: Stroke Honor Roll Elite Plus and Target: Type 2 Diabetes Honor Roll designations.

San Francisco – September 13, 2026 -- Cionic reported that the first 60 participants in its TRANSFORM study showed an average 26% improvement in health-related quality of life after one month, using the standardized EQ-5D-5L instrument across all five measured dimensions.

Cionic launches 12-month study tracking 1,000 adults with upper motor neuron conditions

The TRANSFORM study follows 1,000 adults with multiple sclerosis, stroke, spinal cord injury, cerebral palsy, and related conditions over 12 months, collecting quality-of-life data through six surveys administered via the Cionic mobile app at onboarding and at one, three, six, nine, and 12 months. The primary endpoint, EQ-5D-5L, measures mobility, self-care, usual activities, pain, and anxiety/depression, while secondary measures track spasticity, urinary incontinence, and fatigue.